Piper Sandler analyst Yasmeen Rahimi upgraded Aligos Therapeutics (ALGS) to Overweight from Neutral with a price target of $3, up from $2, following peer Madrigal Pharmaceuticals’ (MDGL) "highly encouraging" resmetirom data, which she sees validating the mechanism of action in NASH. Rahimi, who believes that ALG-055009 has a "competitive and potentially differentiated drug profile," anticipates significant investor interest in Aligos’ NASH asset and also believes that the company has a "compelling" HBV franchise and COVID asset with momentum coming into 2023.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ALGS:
- Jefferies upgrades Aligos to Buy on derisking of NASH pill
- Aligos Therapeutics upgraded to Buy from Hold at Jefferies
- Aligos on track to complete Phase 2-enabling activities in 2023 for ALG-055009
- Aligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009
- Aligos Therapeutics initiates dosing in ALG-125755 trial
